Journal of Radiopharmaceuticals and Molecular Probes (대한방사성의약품학회지)

Korean Society of Radiopharmaceuticals and Molecular Probes (대한방사성의약품학회)
권호 표지
DOI QR코드

DOI QR Code

Recent Progress in Alpha-emitting Radiopharmaceutical Development for Clinical Application

  • Choong Mo Kang (RI Translational Research Team, Division of Applied RI, Korea Institute of Radiological & Medical Sciences) ;
  • Yearn Seong Choe (Department of Nuclear Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine)
  • Received : 2022.12.14
  • Accepted : 2022.12.21
  • Published : 2022.12.30
Download PDF
⟨ Previous Next ⟩

Abstract

Targeted alpha therapy began to be applied to the treatment of late-stage cancer patients because of its dramatic therapeutic efficacy in patients who have no responses with beta-emitting radiopharmaceuticals. However, its strong cytotoxicity may cause side effects due to undesirable uptake in non-target tissues. In order to use alpha-emitting radiopharmaceuticals for early-stage patients as well as late-stage cancer patients, therefore, modifications on their chemical structures are required. In this review, the recent progress in the development of alpha-emitting radiopharmaceuticals is discussed.

Keywords

Acknowledgement

This research was supported by the National Research Foundation of Korea (NRF) grants funded by the Korean government (MSIT) (No. 2021R1F1A1047996 (CMK) and 2020R1A2C1008192 (YSC)). No potential conflicts of interest were disclosed by authors.

References

  1. Barbara Hertz. A tribute to Dr. Saul Hertz: The discovery of the medical uses of radioiodine. World J Nucl Med 2019;18(1):8-12. https://doi.org/10.4103/wjnm.WJNM_107_18
  2. Sgrouros G, Bodei L, McDevitt MR, Nedrow JR. Radiopharmaceutical therapy in cancer: clinical advances and challenges. Nat Rev Drug Discov 2020;19:589-608. https://doi.org/10.1038/s41573-020-0073-9
  3. Herrera FG, Bourhis J, Coukos G. Radiotherapy combination opportunities leveraging immunity for the next oncology practice. CA Cancer J Clin 2017;67:65-85. https://doi.org/10.3322/caac.21358
  4. Haberkorn U, Giesel FL, Morgenstern A, Kratochwil C. The future of radioligand therapy: α, β, or both? J Nucl Med 2017;58:1017-8. https://doi.org/10.2967/jnumed.117.190124
  5. Kratochwil C, Giesel FL, Bruchertseifer F, Mier W, Apostolidis C, Boll R, Murphy K, Haberkorn U, Morgenstern A. 213Bi-DOTATOC receptor-targeted alpha-radionuclide therapy induces remission in neuroendocrine tumours refractory to beta radiation: a first-in-human experience. Eur J Nucl Med Mol Imaging 2014;41(11):2106-9. https://doi.org/10.1007/s00259-014-2857-9
  6. Menager J, Gorin JB, Maurel C, Drujont L, Gouard S, Louvet C, Cherel M, Faivre-Chauvet A, Morgenstern A, Bruchertseifer F, Davodeau F, Gaschet J, Guilloux Y. Combining α-radioimmunotherapy and adoptive T cell therapy to potentiate tumor destruction. Plos one 2015;10(6):e0130249.
  7. Gorin JB, Menager J, Gouard S, Maurel C, Guilloux Y, Faivre-Chauvet A, Morgenstern A, Bruchertseifer F, Cherel M, Davodeau F, Gaschet J. Antitumor immunity induced after α irradiation 1, 2, 3. Neoplasia 2014;16:319-28. https://doi.org/10.1016/j.neo.2014.04.002
  8. Allen BJ. Targeted alpha therapy: evidence for potential efficacy of alpha-immunoconjugates in the management of micrometastatic cancer. Australas Radiol 1999;43:480-6. https://doi.org/10.1046/j.1440-1673.1999.00717.x
  9. Kratochwil C, Bruchertseifer F, Rathke H, Hohenfellner M, Giesel FL, Haberkorn U, Morgenstern A. Targeted α-Therapy of Metastatic Castration-Resistant Prostate Cancer with 225Ac-PSMA-617: Swimmer-Plot Analysis Suggests Efficacy Regarding Duration of Tumor Control. J Nucl Med 2018;59(5):795-802. https://doi.org/10.2967/jnumed.117.203539
  10. Sathekge M, Bruchertseifer F, Knoesen O, Reyneke F, Lawal I, Lengana T, Davis C, Mahapane J, Corbett C, Vorster M, Morgenstern A. 225Ac-PSMA-617 in chemotherapy-naive patients with advanced prostate cancer: a pilot study. Eur J Nucl Med Mol Imaging 2019;46(1):129-38. https://doi.org/10.1007/s00259-018-4167-0
  11. Khreish F, Ebert N, Ries M, Maus S, Rosar F, Bohnenberger H, Stemler T, Saar M, Bartholoma M, Ezziddin S. 225Ac-PSMA-617/ 177Lu-PSMA-617 tandem therapy of metastatic castration-resistant prostate cancer: pilot experience. Eur J Nucl Med Mol Imaging 2020;47(3):721-8. https://doi.org/10.1007/s00259-019-04612-0
  12. Kratochwil C, Bruchertseifer F, Giesel FL, Apostolidis C, Haberkorn U, Morgenstern A. Ac-225-DOTATOC - an empiric dose finding for alpha particle emitter based radionuclide therapy of neuroendocrine tumors. J Nucl Med 2015;56(s3):1232.
  13. Makvandi M, Dupis E, Engle JW, Nortier FM, Fassbender ME, Simon S, Birnbaum ER, Atcher RW, John KD, Rixe O, Norenberg JP. Alpha-Emitters and Targeted Alpha Therapy in Oncology: from Basic Science to Clinical Investigations. Target Oncol 2018;13:189-203. https://doi.org/10.1007/s11523-018-0550-9
  14. Song H, Hobbs RF, Vajravelu R, Huso DL, Esaias C, Apostolidis C, Morgenstern A, Sgouros G. Radioimmunotherapy of breast cancer metastases with alpha-particle emitter 225Ac: comparing efficacy with 213Bi and 90Y. Cancer Res 2009;69:8941-8. https://doi.org/10.1158/0008-5472.CAN-09-1828
  15. Kratochwil C, Bruchertseifer F, Rathke H, Bronzel M, Apostolidis C, Weichert W, Haberkorn U, Giesel FL, Morgenstern A. Targeted α-Therapy of Metastatic Castration-Resistant Prostate Cancer with 225Ac-PSMA-617: Dosimetry Estimate and Empiric Dose Finding. J Nucl Med 2017;58(10):1624-31. https://doi.org/10.2967/jnumed.117.191395
  16. Langbein T, Chausse G, Baum RP. Salivary gland toxicity of PSMA radioligand therapy: relevance and preventive strategies. J Nucl Med 2018;59:1172-3. https://doi.org/10.2967/jnumed.118.214379
  17. Dekempeneer Y, Keyaerts M, Krasniqi A, Puttemans J, Muyldermans S, Lahoutte T, D'huyvetter M, Devoogdt N. Targeted alpha therapy using short-lived alpha-particles and the promise of nanobodies as targeting vehicle. Expert Opin Biol Ther 2016;16:1035-47. https://doi.org/10.1080/14712598.2016.1185412
  18. Miederer M, McDevitt MR, Sgouros G, Kramer K, Cheung NK, Scheinberg DA. Pharmacokinetics, dosimetry, and toxicity of the targetable atomic generator, 225Ac-HuM195, in nonhuman primates. J Nucl Med 2004;45(1):129-37.
  19. Jurcic JG, Rosenblat TL, McDevitt MR, Pandit-Taskar N, Carrasquillo JA, ChanelC. Ryan SM, Frattini MG, Cicic D, Larson SM, Scheinberg DA. Phase I trial of the targeted alpha-particle nano-generator actinium-225 (225Ac-lintuzumab) (anti-CD33; HuM195) in acute myeloid leukemia (AML). J Clin Oncol 2011;29:Abstract 6516.
  20. Jurcic JG, Ravandi F, Pagel JM, Park JH, Douer D, Estey EH, Kantarjian HM, Cicic D, Scheinberg DA. Phase I trial of the targeted alpha-particle nano-generator actinium-225 (225Ac)-lintuzumab (anti-CD33) in combination with low-dose cytarabine (LDAC) for older patients with untreated acute myeloid leukemia (AML). Blood 2013;122(21):1460.
  21. Borchardt PE, Yuan RR, Miederer M, McDevitt MR, Scheinberg DA. Targeted actinium-225 in vivo generators for therapy of ovarian cancer. Cancer Res 2003;63(16):5084-90.
  22. Tagawa ST, Sun M, Sartor AO, Thomas C, Singh S, Bissassar M, Fernandez E, Niaz MJ, Ho B, Vallabhajosula S, Babich J, Molina AM, Sternberg CN, Nanus DM, Osborne J, Bander NH. Phase I study of 225Ac-J591 for men with metastatic castration-resistant prostate cancer (mCRPC). J Clin Oncol 2021;39(15):suppl.5015.
  23. Meyer C, Stuparu A, Wei L, Capri J, Le T, Radu C, Czernin J, Dahlbom M, Slavik R. Therapeutic efficacy and dosimetry of Targeted alpha therapy using 225Ac-PSMA-617 in a murine model of prostate cancer. J Med Imaging Radiat Sci 2019;50:S93-4.
  24. Stuparu AD, Meyer CAL, Evans-Axelsson SL, Luckerath K, Wei LH, Kim W, Poddar S, Mona CE, Dahlbom M, Girgis MD, Radu CG, Czernin J, Slavik R. Targeted alpha therapy in a systemic mouse model of prostate cancer - a feasibility study. Theranostics 2020;10(6):2612-20. https://doi.org/10.7150/thno.42228
  25. Current K, Meyer C, Magyar CE, Mona CE, Almajano J, Slavik R, Stuparu AD, Cheng C, Dawson DW, Radu CG, Czernin J, Lueckerath K. Investigating PSMA-targeted radioligand therapy efficacy as a function of cellular PSMA levels and intratumoral PSMA heterogeneity. Clin Cancer Res 2020;26(12):2946-55. https://doi.org/10.1158/1078-0432.CCR-19-1485
  26. Czernin J, Current K, Mona CE, Nyiranshuti L, Hikmat F, Radu CG, Lueckerath K. Immune-checkpoint blockade enhances 225Ac-PSMA617 efficacy in a mouse model of prostate cancer. J Nucl Med 2020;62:228-31.
  27. Kratochwil C, Bruchertseifer F, Giesel FL, Weis M, Verburg FA, Mottaghy F, Kopka K, Apostolidis C, Haberkorn U, Morgenstern A. 225Ac-PSMA-617 for PSMA-targeted alpha-radiation therapy of metastatic castration-resistant prostate prostate cancer. J Nucl Med 2016;57:1941-4. https://doi.org/10.2967/jnumed.116.178673
  28. Sathekge M, Bruchertseifer F, Vorster M, Lawal IO, Knoesen O, Mahapane J, Davis C, Reyneke F, Maes A, Kratochwil C, Lengana T, Giesel FL, Van de Wiele C, Morgenstern A. Predictors of overall and disease-free survival in metastatic castration-resistant prostate cancer patients receiving 225Ac-PSMA-617 radioligand therapy. J Nucl Med 2020;61(1):62-9. https://doi.org/10.2967/jnumed.119.229229
  29. Yadav MP, Ballal S, Sahoo RK, Tripathi M, Seth A, Bal C. Efficacy and safety of 225Ac-PSMA-617 targeted alpha therapy in metastatic castration-resistant prostate cancer patients. Theranostics 2020;10:9364-77. https://doi.org/10.7150/thno.48107
  30. Van der Doelen MJ, Mehra N, Van Oort IM, Looijen-Salamon MG, Janssen MJR, Custers JAE, Slootbeek PHJ, Kroeze LI, Bruchertseifer F, Morgenstern A, Haberkorn U, Kratochwil C, Nagarajah J, Gerritsen WR. Clinical outcomes and molecular profiling of advanced metastatic castration-resistant prostate cancer patients treated with 225Ac-PSMA-617 targeted alpha-radiation therapy. Urol Oncol 2021;39(10)729.e7-e16.
  31. Ilhan H, Gosewisch A, Boning G, Volter F, Zacherl M, Unterrainer M, Bartenstein P, Todica A, Gildehaus FJ. Response to 225Ac-PSMA-I&T after failure of long-term 177Lu-PSMA RLT in mCRPC. Eur J Nucl Med Mol Imaging 2021;48:1262-3. https://doi.org/10.1007/s00259-020-05023-2
  32. Zacherl MJ, Gildehaus FJ, Mittlmeier L, Boning G, Gosewisch A, Wenter V, Unterrainer M, Schmidt-Hegemann N, Belka C, Kretschmer A, Casuscelli J, Stief CG, Unterrainer M, Bartenstein P, Todica A, Ilhan H. First clinical results for PSMA-targeted α-therapy using 225Ac-PSMA-I&T in advanced-mCRPC patients. J Nucl Med 2021;62(5):669-74. https://doi.org/10.2967/jnumed.120.251017
  33. Miederer M, Henriksen G, Alke A, Mossbrugger I, Quintanilla-Martinez L, Senekowitsch-Schmidtke R, Essler M. Preclinical evaluation of the α-particle generator nuclide 225Ac for somatostatin receptor radiotherapy of neuroendocrine tumors. Clin Cancer Res 2008;14(11):3555-61. https://doi.org/10.1158/1078-0432.CCR-07-4647
  34. Kratochwil C, Apostolidis L, Rathke H, Apostolidis C, Bicu F, Brucherseifer F, Choyke PL, Haberkorn U, Giesel F, Morgenstern A. Dosing 225Ac-DOTATOC in patients with somatostatin-receptor-positive solid tumors: 5-year follow-up of hematological and renal toxicity. Eur J Nucl Med Mol Imaging 2021;49(1):54-63. https://doi.org/10.1007/s00259-021-05474-1
  35. Zalutsky MR, Garg PK, Friedman HS, Bigner DD. Labeling monoclonal antibodies and F (ab') fragments with the alpha-particle-emitting nuclide astatine-211: preservation of immunoreactivity and in vivo localizing capacity. Proc Natl Acad Sci 1989;86(18):7149-53. https://doi.org/10.1073/pnas.86.18.7149
  36. Zalutsky MR, Stabin MG, Larsen RH, Bigner DD. Tissue distribution and radiation dosimetry of astatine-211-labeled chimeric 81C6, an alpha-particle-emitting immunoconjugate. Nucl Med Biol 1997;24(3):255-61. https://doi.org/10.1016/S0969-8051(97)00060-7
  37. Zalutsky MR, Reardon DA, Akabani G, Coleman RE, Friedman AH, Friedman HS, McLendon RE, Wong TZ, Bigner DD. Clinical experience with alpha-particle emitting 211At: treatment of recurrent brain tumor patients with 211At-labeled chimeric antitenascin monoclonal antibody 81C6. J Nucl Med 2008;49(1):30-8. https://doi.org/10.2967/jnumed.107.046938
  38. Elgqvist J, Andersson H, Back T, Claesson I, Hultborn R, Jensen H, Lindegren S, Olsson M, Palm S, Warnhammar E, Jacobsson L. Fractionated radioimmunotherapy of intraperitoneally growing ovarian cancer in nude mice with 211At-MX35 F(ab')2: therapeutic efficacy and myelotoxicity. Nucl Med Biol 2006;33(8):1065-72. https://doi.org/10.1016/j.nucmedbio.2006.07.009
  39. Andersson H, Cederkrantz E, Back T, Divgi C, Elgqvist J, Himmelman J, Horvath G, Jacobsson L, Jensen H, Lindergren S, Palm S, Hultborn R. Intraperitoneal α-particle radioimmunotherapy of ovarian cancer patients: pharmacokinetics and dosimetry of 211At-MX35 F(ab')2-a phase I study. J Nucl Med 2009;50(7):1153-60. https://doi.org/10.2967/jnumed.109.062604
  40. Andersson H, Lindergren S, Back T, Jacobsson L, Leser G, Horvath G. The curative and palliative potential of the monoclonal antibody MOv18 labelled with 211At in nude mice with intraperitoneally growing ovarian cancer xenografts-a long-term study. Acta Oncologica 2000;39(6):741-5. https://doi.org/10.1080/028418600750063820
  41. Reist CJ, Foulon CF, Alston K, Bigner DD, Zalutsky MR. Astatine-211 labeling of internalizating anti-EGFRvIII monoclonal antibody using N-succinimidyl 5-[211At]astato-3-pyridinecarboxylate. Nucl Med Biol 1999;26(4):405-11. https://doi.org/10.1016/S0969-8051(98)00120-6
  42. Robinson MK, Shaller C, Garmestani K, Plascjak PS, Hodge KM, Yuan QA, Marks JD, Waldmann TA, Brechbiel MW, Adams GP. Effective treatment of established human breast tumor xenografts in immunodeficient mice with a single dose of the alpha-emitting radioisotope astatine-211 conjugated to anti-HER2/neu diabodies. Clin Cancer Res 2008;14(3):875-82. https://doi.org/10.1158/1078-0432.CCR-07-1250
  43. Steffen AC, Almqvist Y, Chyan MK, Lundqvist H, Tolmachev V, Wilbur DS, Carlsson J. Biodistribution of 211At labeled HER-2 binding affibody molecules in mice. Oncol Rep 2007;17(5):1141-7.
  44. Nikula TK, McDevitt MR, Finn RD, Wu C, Kozak RW, Garmestani K, Brechbiel MW, Curcio MJ, Pippin CG, Tiffany-Jones L, Geerlings Sr MW, Apostolidis C, Molinet R, Geerlings Jr MW, Gansow OA, Scheinberg DA. Alpha-emitting bismuth cyclohexylbenzyl DTPA constructs of recombinant humanized anti-CD33 antibodies: pharmacokinetics, bioactivity, toxicity and chemistry. J Nucl Med 1999;40(1):166-76.
  45. Schwartz J, Jaggi JS, O'Donoghue JA, Ruan S, McDevitt M, Larson SM, Scheinberg DA, Humm JL. Renal uptake of bismuth-213 and its contribution to kidney radiation dose following administration of actinium-225-labeled antibody. Phy Med Biol 2011;56(3):721-33. https://doi.org/10.1088/0031-9155/56/3/012
  46. Jurcic JG, Larson SM, Sgouros G, McDevitt MR, Finn RD, Divgi CR, Ballangrud AM, Hamacher KA, Ma D, Humm JL, Brechbiel MW, Molinet R, Scheinberg DA. Targeted alpha particle immunotherapy for myeloid leukemia. Blood 2002;100(4):1233-9. https://doi.org/10.1182/blood.V100.4.1233.h81602001233_1233_1239
  47. Rosenblat TL, McDevitt MR, Mulford DA, Pandit-Taskar N, Divgi CR, Panageas KS, Heaney ML, Chanel S, Morgenstern A, Sgouros G, Larson SM, Scheinberg DA, Jurcic JG. Sequential cytarabine and alpha-particle immunotherapy with bismuth-213-lintuzumab (HuM195) for acute myeloid leukemia. Clin Cancer Res 2010;16(21):5303-11. https://doi.org/10.1158/1078-0432.CCR-10-0382
  48. Park SI, Shenoi J, Pagel JM, Hamlin DK, Wilbur DS, Orgun N, Kenoyer AL, Frayo S, Axtman A, Back T, Lin Y, Fisher DR, Gopal AK, Green DJ, Press OW. Conventional and pretargeted radioimmunotherapy using bismuth-213 to target and treat non-Hodgkin lymphomas expressing CD20: a preclinical model toward optimal consolidation therapy to eradicate minimal residual disease. Blood 2010;116(20):4231-9.
  49. Roscher M, Hormann I, Leib O, Marx S, Moreno J, Miltner E, Friesen C. Targeted alpha-therapy using [Bi-213]anti-CD20 as novel treatment option for radio- and chemoresistant non-Hodgkin lymphoma cells. Oncotarget 2013;4(2):218-30. https://doi.org/10.18632/oncotarget.817
  50. Heeger S, Moldenhauer G, Egerer G. Alpha-radioimmunotherapy of B-lineage non-Hodgkin's lymphoma using 213Bi-labelled anti-CD19-and anti-CD20-CHX-A"-DTPA conjugates. ACS Meeting Abstracts 2003;225:U261.
  51. Vandenbulcke K, De Vos F, Offner F, Philippe J, Apostolidis C, Molinet R, Nikula TK, Bacher K, de Gelder V, Vral A, Lahorte C, Thierens H, Dierckx R, Slegers G. In vitro evaluation of 213Bi-rituximab versus external gamma irradiation for the treatment of B-CLL patients: relative biological efficacy with respect to apoptosis induction and chromosomal damage. Eur J Nucl Med Mol Imaging 2003;30(10):1357-64. https://doi.org/10.1007/s00259-003-1228-8
  52. Cordier D, Forrer F, Bruchertseifer F, Morgenstern A, Apostolidis C, Good S, Muller-Brand J, Macke H, Reubi JC, Merlo A. Targeted alpha-radionuclide therapy of functionally critically located gliomas with 213Bi-DOTA-TA-[Thi8, Met(O2)11]-substance P: a pilot trial. Eur J Nucl Med Mol Imaging 2010;37(3):335-44.
  53. Morgenstern A, Krolicki L, Kunikowska J, Koziara H, Krolicki B, Jakucinski M, Apostolidis C, Bruchertseifer F. Targeted alpha therapy of glioblastoma multiforme: First clinical experience with 213Bi-substance P. J Nucl Med 2014;55(supplement 1):390.
  54. Krolicki L, Bruchertseifer F, Kunikowska J, Koziara H, Krolicki B, Jakucinski M, Pawlak D, Apostolidis C, Mirzadeh S, Rola R, Merlo A, Morgenstern A. Safety and efficacy of targeted alpha therapy with 213Bi-DOTA-substance P in recurrent glioblastoma. Eur J Nucl Med Mol Imaging 2019;46(3):614-22. https://doi.org/10.1007/s00259-018-4225-7
  55. Rizvi SMA, Allen BJ, Tian Z, Goozee G, Sarkar S. In vitro and preclinical studies of targeted alpha therapy (TAT) for colorectal cancer. Color Dis 2001;3(5):345-53. https://doi.org/10.1046/j.1463-1318.2001.00264.x
  56. Li Y, Wang J, Rizvi SMA, Jager MJ, Conway RM, Billson FA, Allen BJ, Madigan MC. In vitro targeting of NG2 antigen by 213Bi-9.2.27 α-immunoconjugate induces cytotoxicity in human uveal melanoma cells. Investig Ophthalmol Vis Sci 2005;46(12):4365-71. https://doi.org/10.1167/iovs.05-0559
  57. Allen BJ, Singla AA, Rizvi SMA, Graham P, Bruchertseifer F, Apostolidis C, Morgenstern A. Analysis of patient survival in a phase I trial of systemic targeted α-therapy for metastatic melanoma. Immunotherapy 2011;3(9):1041-50. https://doi.org/10.2217/imt.11.97
  58. Raja C, Graham P, Rizvi SMA, Song E, Goldsmith H, Thompson J, Bosserhoff A, Morgenstern A, Apostolidis C, Kearsley J, Reisfeld R, Allen BJ. Interim analysis of toxicity and response in phase 1 trial of systemic targeted alpha therapy for metastatic melanoma. Cancer Biol Ther 2007;6(6):846-52. https://doi.org/10.4161/cbt.6.6.4089
  59. Allen BJ, Raja C, Rizvi S, Li Y, Tsui W, Graham P, Thompson J, Reisfeld R, Kearsley J, Morgenstern A, Apostolidis C. Intralesional targeted alpha therapy for metastatic melanoma. Cancer Biol Ther 2005;4(12):1318-24. https://doi.org/10.4161/cbt.4.12.2251
  60. Norenberg JP, Krenning BJ, Konings IRHM, Kusewitt DF, Nayak TK, Anderson TL, de Jong M, Garmestani K, Brechbiel MW, Kvols LK. 213Bi-[DO-TA0, Tyr3]Octreotide Peptide Receptor Radionuclide Therapy of Pancreatic Tumors in a Preclinical Animal Model. Clin Cancer Res 2006;12(3):897-903. https://doi.org/10.1158/1078-0432.CCR-05-1264
  61. Kratochwil C, Giesel FL, Bruchertseifer F, Mier W, Apostolidis C, Boll R, Murphy K, Haberkorn U, Morgenstern A. 213Bi-DOTATOC receptor-targeted alpha-radionuclide therapy induces remission in neuroendocrine tumours refractory to beta radiation: a first-in-human experience. Eur J Nucl Med Mol Imaging 2014;41(11):2106-19. https://doi.org/10.1007/s00259-014-2857-9
  62. Heyerdahl H, Abbas N, Brevik EM, Mollatt C, Dahle J. Fractionated therapy of HER2-expressing breast and ovarian cancer xenografts in mice with targeted alpha emitting 227Th-DOTA-p-benzyl-trastuzumab. PLoS One 2012;7(8): e42345.
  63. Heyerdahl H, Abbas N, Sponheim K, Mollatt C, Bruland O, Dahle J. Targeted alpha therapy with 227Th-trastuzumab of intraperitoneal ovarian cancer in nude mice. Curr Radiopharm 2013;6(2):106-16. https://doi.org/10.2174/18744710113069990018
  64. Melhus KB, Larsen RH, Stokke T, Kaalhus O, Selbo PK, Dahle J. Evaluation of the binding of radiolabeled rituximab to CD20-positive lymphoma cells: an in vitro feasibility study concerning low-dose-rate radioimmunotherapy with the α-emitter 227Th. Cancer Biother Radiopharm 2007;22(4):469-79.
  65. Dahle J, Jonasdottir TJ, Heyerdahl H, Nesland JM, Borrebaek J, Hjelmerud AK, Larsen RH. Assessment of long-term radiotoxicity after treatment with the low-dose-rate alpha-particle-emitting radioimmunoconjugate 227Th-rituximab. Eur J Nucl Med Mol Imaging 2010;37(1):93-102. https://doi.org/10.1007/s00259-009-1197-7
  66. Tan Z, Chen P, Schneider N, Glover S, Cui L, Torgue J, Rixe O, Spitz HB, Dong Z. Significant systemic therapeutic effects of high-LET immunoradiation by 212Pb-trastuzumab against prostatic tumors of androgen-independent human prostate cancer in mice. Int J Oncol 2012;40(6):1881-8.
  67. Yong K, Brechbiel M. Application of 212Pb for targeted α-particle therapy (TAT): preclinical and mechanistic understanding through to clinical translation. AIMS Med Sci 2015;2(3):228-45. https://doi.org/10.3934/medsci.2015.3.228
  68. Meredith R, Torgue J, Shen S, Fisher DR, Banaga E, Bunch P, Morgan D, Fan J, Straughn JM Jr. Dose escalation and dosimetry of first-in-human α radioimmunotherapy with 212Pb-TCMC-trastuzumab. J Nucl Med 2014;55(10):1636-42. https://doi.org/10.2967/jnumed.114.143842
  69. Meredith R, Torgue J, Azure MT, Shen S, Saddekni S, Banaga E, Carlise R, Bunch P, Yoder D, Alvarez R. Pharmacokinetics and imaging of 212Pb-TCMC-trastuzumab after intraperitoneal administration in ovarian cancer patients. Cancer Biother Radiopharm 2014;29(1):12-7.
  70. Henriksen G, Breistol K, Bruland OS, Fodstad O, Larsen RH. Significant antitumor effect from bone-seeking, alpha-particle-emitting 223Ra demonstrated in an experimental skeletal metastases model. Cancer Res 2002;62(11): 3120-5.
  71. Parker C, Nilsson S, Heinrich D, Helle SI, O'Sullivan JM, Fossa SD, Chodacki A, Wiechno P, Logue J, Seke M, Widmark A, Johannessen DC, Hoskin P, Bottomley D, James ND, Solberg A, Syndikus I, Kliment J, Wedel S, Boehmer S, Dall'Oglio M, Franzen L, Coleman R, Vogelzang NJ, O'Bryan-Tear CG, Staudacher K, Garcia-Vargas J, Shan M, Bruland OS, Sartor O, ALSYMPCA Investigators. Alpha emitter radium-223 and survival in metastatic prostate cancer. N Engl J Med 2013;369(3):213-23. https://doi.org/10.1056/NEJMoa1213755
  72. Nilsson S, Larsen RH, Fossa SD, Belteskard L, Borch KW, Westlin JE, Salberg G, Bruland OS. First clinical experience with alpha-emitting radium-223 in the treatment of skeletal metastases. Clin Cancer Res 2005;11(12):4451-9. https://doi.org/10.1158/1078-0432.CCR-04-2244
  73. Cheung NKV, Modak S, Lin Y, Guo H, Zanzonico P, Chung J, Zuo Y, Sanderson J, Wilbert S, Theodore LJ, Axworthy DB, Larson SM. Single-chain Fv-streptavidin substantially improved therapeutic index in multistep targeting directed at disialoganglioside GD2. J Nucl Med 2004;45(5):867-77.
  74. Frost SHL, Frayo SL, Miller BW, Orozco JJ, Booth GC, Hylarides MD, Lin Y, Green DJ, Gopal AK, Pagel JM, Back TA, Fisher DR, Press OW. Comparative efficacy of 177Lu and 90Y for anti-CD20 pretargeted radioimmunotherapy in murine lymphoma xenograft models. PLoS One 2015;10(3):e0120561.
  75. Houghton JL, Membreno R, Abdel-Atti D, Cunanan KM, Carlin S, Scholz WW, Zanzonico PB, Lewis JS, Zeglis BM. Establishment of the in vivo efficacy of pretargeted radioimmunotherapy utilizing inverse electron demand diels-alder click chemistry. Mol Cancer Ther 2017;16(1):124-33.
  76. Poty S, Carter LM, Mandleywala K, Membreno R, Abdel-Atti D, Ragupathi A, Scholz WW, Zeglis BM, Lewis JS. Leveraging bioorthogonal click chemistry to improve 225Ac-radioimmunotherapy of pancreatic ductal adenocarcinoma. Clin Cancer Res 2019;25(2):868-80. https://doi.org/10.1158/1078-0432.CCR-18-1650
  77. Reiner T, Zeglis BM. The inverse electron demand Diels-Alder click reaction in radiochemistry. J Labelled Comp Radiopharm 2014;57(4):285-90. https://doi.org/10.1002/jlcr.3149
  78. NA, Schlyer D, Wilson JJ, DiMagno SG, Babich JW. A single dose of 225Ac-RPS-074 induces a complete tumor response in an LNCaP xenograft model. J Nucl Med 2019;60(5):649-55. https://doi.org/10.2967/jnumed.118.219592
  79. Thijssen L, Schaart DR, de Vries D, Morgenstern A, Bruchertseifer F, Denkova AG. Polymersomes as nano-carriers to retain harmful recoil nuclides in alpha radionuclide therapy: a feasibility study. Radiochim Acta 2012;100:473-82. https://doi.org/10.1524/ract.2012.1935
  80. Jaggi JS, Kappel BJ, McDevitt MR, Sgouros G, Flombaum CD, Cabassa C, Scheinberg DA. Efforts to control the errant products of a targeted in vivo generator. Cancer Res 2005;65(11):4888-95. https://doi.org/10.1158/0008-5472.CAN-04-3096
  81. Schwartz J, Jaggi JS, O'Donoghue JA, Ruan S, McDevitt M, Larson SM, Scheinberg DA, Humm JL. Renal uptake of bismuth-213 and its contribution to kidney radiation dose following administration of actinium-225-labeled antibody. Phys Med Biol 2011;56(3):721-33. https://doi.org/10.1088/0031-9155/56/3/012
  82. Bartos B, Lyczko K, Kasperek A, Krajewski S, Bilewicz A. Search of ligands suitable for 212Pb/212Bi in vivo generators. J Radioanal Nucl Chem 2013;295:205-9. https://doi.org/10.1007/s10967-012-2238-4
  83. Delpassand ES, Tworowska I, Esfandiari R, Torgue J, Hurt J, Shafie A, Nunez R. Targeted α-emitter therapy with 212Pb-DOTAMTATE for the treatment of metastatic SSTR-expressing neuroendocrine tumors: first-in-humans dose-escalation clinical trial. J Nucl Med 2022;63(9):1326-33 https://doi.org/10.2967/jnumed.121.263230